In this issue:
Association of a marker of GlcNAc with progressive MS and neurodegeneration
Breast cancer survival in MS
Association of central hypersomnia and fatigue in MS
Safety of the BNT162b2 COVID-19 vaccine in MS
Early factors associated with later conversion to MS in patients presenting with isolated myelitis
AHSCT as a first-line DMT in patients with ‘aggressive’ MS
De-escalating rituximab dose results in stability of clinical, radiological, and sNfL levels in MS
Factors impacting on HRQoL with MS, irrespective of clinical phenotype
A real-world analysis of alemtuzumab and cladribine for MS
MS-like NMOSD patients suffer severe worsening of status after fingolimod initiation
Please login below to download this issue (PDF)